Drug intelligence / Profile preview

Qianlong Shutong Formula

Development stage: Discontinued
Lead developer: Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine
Administration: Oral

Overview

Qianlong Shutong Formula is a Traditional Chinese Medicine (TCM) herbal prescription developed by Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine. It is specifically formulated for the treatment of benign prostatic hyperplasia (BPH), targeting the kidney qi deficiency pattern common in TCM diagnostics. The formula is intended to be used as a therapeutic intervention to improve lower urinary tract symptoms and overall clinical outcomes in BPH patients. A clinical trial (ChiCTR2300070957) was initiated to evaluate the efficacy and safety of the formula in combination with tamsulosin hydrochloride, although the study was ultimately canceled by the investigator.

Other names: Qianlong Shutong prescription

Targets

STAT3 (Signal Transducer and Activator of Transcription 3)HRAS (H-Ras protein)PIK3CA (Phosphoinositide 3-kinase alpha)EP300 (Histone acetyltransferase p300 (EP300) catalytic domain)PIK3R1 (Phosphoinositide-3-kinase regulatory subunit 1)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)HSP90AA1 (Heat shock protein HSP90-alpha)GRB2 (Growth factor receptor-bound protein 2)MAPK3 (Mitogen-activated protein kinase 1)

Beyond the preview

Go deeper on Qianlong Shutong Formula.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qianlong Shutong Formula.

Explore the full profile